Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566774 · ClinicalTrials.gov registry record · Phase 4
A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,860
- Enrollment target
NCT00566774: Completed Phase 4 study, sponsored by Brigham and Women's Hospital.
NCT00566774 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 5,860 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1031% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566774, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,860 participants
- Enrollment target
Study Summary
The objective of this randomized trial is to evaluate the effect of providing full prescription drug coverage (i.e. no co-pays, co-insurance or deductibles) for statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to patients recently discharged from hospital after acute myocardial infarction.
Interventions
- OTHER Full drug coverage
- OTHER Usual coverage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,860 participants |
| Start Date | 2007-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
What the finished NCT00566774 record still lists
NCT00566774 is an interventional study that assigns participants to a tested intervention. Its 5,860 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1031% higher).
The record links to 0 conditions, and to 2 interventions - of which Full drug coverage is the first listed.
NCT00566774 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00566774 about?
NCT00566774 is a clinical study titled "A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies". The objective of this randomized trial is to evaluate the effect of providing full prescription drug coverage (i.e. no co-pays, co-insurance or deductibles) for statins, beta-blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers to patients recently discharged from ...
What is the current status of trial NCT00566774?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,860 participants. The study started on 2007-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00566774?
The interventions under investigation include: Full drug coverage (OTHER), Usual coverage (OTHER).
Who is sponsoring clinical trial NCT00566774?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00566774's enrollment target sits among peer trials
5,860 15th of 2000 higher than 1,986 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia